ResMed FQ1 revenue driven by demand for mask product portfolio, ventilators

• ResMed (RMD +5.9%) FQ1 result shows revenue increase of 10% to $751.9M.
• Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 9%, driven by strong sales across our mask product portfolio and increased demand for our ventilators due to COVID-19.
• GAAP gross margin of 58.3% vs. last year's 57.5%.
• R&D expenses of $54.5M vs. $48M.
• Net operating profit increased 27%; non-GAAP operating profit up 24%.
• Cash and equivalents of $421.41M.
• GAAP EPS of $1.22 vs. last year's $0.83.
• Non-GAAP EPS of $1.27 vs. last year's $0.93
• https://seekingalpha.com/news/3629134-resmed-shareplus-5_8-fq1-revenue-driven-demand-for-mask-product-portfolio-and-ventilators